Supplementary Table 3. Univariate linear regression analysis of percent change of eGFR during first week and variables

	Univariate									
	Total (n = 108)		Total except for 1B (n = 107)		1C (n = 36)		1D (n = 37)		1E (n = 34)	
	ß	p-value	ß	p-value	ß	p-value	ß	p-value	ß	p-value
Age	−0.045	0.70	−0.047	0.69	−0.384	0.17	−0.092	0.70	0.224	0.22
Sex (male)	0.514	0.8	0.55	0.79	0.59	0.89	1.111	0.76	2.765	0.52
Systolic blood pressure (mmHg)	−0.071	0.30	−0.07	0.31	−0.024	0.88	−0.194	0.07	0.081	0.42
Diastolic blood pressure (mmHg)	−0.109	0.22	−0.109	0.23	−0.057	0.78	−0.225	0.15	−0.028	0.81
Baseline eGFR (mL/min/1.73 m^2)	−0.013	0.73	−0.012	0.74	0.089	0.36	−0.065	0.30	−0.028	0.55
Baseline htTKV (mL/m)	−0.001	0.55	−0.001	0.56	−0.004	0.60	−0.004	0.29	0.002	0.38
Baseline urine osmolality (mOsm/kg)	0.003	0.53	0.003	0.53	0.004	0.73	−0.006	0.64	0.009	0.20
Change of urine osmolality (mOsm/kg)	−0.009	0.17	−0.009	0.17	−0.007	0.56	−0.035	0.12	0.001	0.86
Weight-adjusted dose of tolvaptan (mg/kg)	4.868	0.56	4.812	0.57	15.542	0.44	3.341	0.83	−5.589	0.64

eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; htTKV, height-adjusted total kidney volume.